2023 World Conference on Lung Cancer (Posters)-EP06.03. Characterization of KRAS Mutations in Black Patients with NSCLC at an Urban Academic Medical Center

EP06.03. Characterization of KRAS Mutations in Black Patients with NSCLC at an Urban Academic Medical Center - PDF(Slides)

Back to course

Pdf Summary

This study aimed to characterize KRAS mutations in black patients with non-small cell lung cancer (NSCLC) at an urban academic medical center. KRAS is a common oncogenic driver of NSCLC, and two drugs, sotorasib and adagrasib, have been approved for the treatment of advanced KRAS G12C NSCLC. However, clinical trials in oncology have shown a lack of representation of Black or African American patients.<br /><br />The researchers conducted a retrospective review of patients with KRAS G12C-mutated NSCLC at Northwestern Memorial Hospital over a period of 7 years. They collected information on stage, histologic type, PDL-1 status, age at diagnosis, race, and smoking history.<br /><br />The results showed that out of the 61 patients who met the inclusion criteria, 14.7% were Black. Among patients with stage IV disease, 13.5% were Black. Black and White patients were similar in age and smoking status, and there were no differences in medical comorbidities.<br /><br />The findings suggest that the percentage of Black patients with KRAS G12C NSCLC at this medical center is higher than those enrolled in clinical trials for the approved therapies. This highlights the need for sponsors of trials to include medical centers that serve diverse patient populations to ensure equitable access to clinical trial involvement for all patients.<br /><br />Overall, this study provides important insights into the representation of Black patients with KRAS G12C NSCLC and emphasizes the need for more inclusive clinical trials in oncology. Future studies should consider interventions to promote equitable access to clinical trials for all patients.

Asset Subtitle

Danielle Dressler

Meta Tag

Speaker Danielle Dressler

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

KRAS mutations

black patients

non-small cell lung cancer

NSCLC

urban academic medical center

oncogenic driver

sotorasib

adagrasib

clinical trials

representation of Black patients